Most notable products launched are Aspen Azithromycin, Diclo-flam, Mybulen capsules and Terbicil. Aspen Azithromycin, a generic of Zithromax, is a novel macrolide used for upper and lower respiratory tract infections. The product offers the unique benefit of short-term therapy (three days) and has captured 10% of the macrolide market. Diclo-flam, a generic of Cataflam, was the first generic to market of a non-steroidal dispersible anti-inflammatory agent. Within a 10-month period, Aspen has captured over 30% of this market. Mybulen capsules, although being the third generic to market, has exceeded expectations and has outgrown the originator’s own generic. Terbicil tablets, a generic of Lamisil, is an agent for the treatment of fungal infections. The product is an affordable alternative to existing generics in the market and has, as a result, superseded their performance. Additional new products include: Aspen Bromocriptine, Aspen Cetirizine, Aspen Lamotrigine, Aspen Pravastatin, Aspen Rampil, Aspen Lanzaprazole, Butobloc, Deparoc, Mybulen suspension and Ondansetron. The entry of Asian and European competitors and patent expiration of many key molecules has created intense generic competition. Despite these changes in the market environment and the challenges imposed by uncertainties in the regulatory environment, all key brands have shown satisfactory growth. Leading brands in the pharmaceutical division include: Product Aspen Lamzid Eltroxin
Description ARV For the treatment of patients with underactive thyroid Mybulen For the treatment of mild to moderate pain Pharmapress For the treatment of hypertension Thinz An appetite suppressant Stilpane For the treatment of general pain and tension pain Flixonase Used prophylactically and for treatment of allergic rhinitis Other leading brands include the ARV range, Cilift, Minerva, Augmentin, Pharmacare Ceftriaxone, Panamor and Flusin.
23
Aspen Annual Report 2006